<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29959962</PMID>
      <DateCompleted>
        <Year>2019</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2019</Year>
        <Month>04</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1097-6787</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>80</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Journal of the American Academy of Dermatology</Title>
          <ISOAbbreviation>J Am Acad Dermatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Onychomycosis: Treatment and prevention of recurrence.</ArticleTitle>
        <Pagination>
          <StartPage>853</StartPage>
          <EndPage>867</EndPage>
          <MedlinePgn>853-867</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaad.2018.05.1260</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0190-9622(18)32187-X</ELocationID>
        <Abstract>
          <AbstractText>Onychomycosis is a fungal nail infection caused by dermatophytes, nondermatophytes, and yeast, and is the most common nail disorder seen in clinical practice. It is an important problem because it may cause local pain, paresthesias, difficulties performing activities of daily living, and impair social interactions. The epidemiology, risk factors, and clinical presentation and diagnosis of onychomycosis were discussed in the first article in this continuing medical education series. In this article, we review the prognosis and response to onychomycosis treatment, medications for onychomycosis that have been approved by the US Food and Drug Administration, and off-label therapies and devices. Methods to prevent onychomycosis recurrences and emerging therapies are also described.</AbstractText>
          <CopyrightInformation>Copyright Â© 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lipner</LastName>
            <ForeName>Shari R</ForeName>
            <Initials>SR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Weill Cornell Medicine, New York, New York. Electronic address: shl9032@med.cornell.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Scher</LastName>
            <ForeName>Richard K</ForeName>
            <Initials>RK</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Dermatology, Weill Cornell Medicine, New York, New York.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>06</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>J Am Acad Dermatol</MedlineTA>
        <NlmUniqueID>7907132</NlmUniqueID>
        <ISSNLinking>0190-9622</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001896">Boron Compounds</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019086">Bridged Bicyclo Compounds, Heterocyclic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058626">Plasma Gases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>19W019ZDRJ</RegistryNumber>
          <NameOfSubstance UI="D000077768">Ciclopirox</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>304NUG5GF4</RegistryNumber>
          <NameOfSubstance UI="D017964">Itraconazole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>8VZV102JFY</RegistryNumber>
          <NameOfSubstance UI="D015725">Fluconazole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>G7RIW8S0XP</RegistryNumber>
          <NameOfSubstance UI="D000077291">Terbinafine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>J82SB7FXWB</RegistryNumber>
          <NameOfSubstance UI="C431707">efinaconazole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>K124A4EUQ3</RegistryNumber>
          <NameOfSubstance UI="C512998">tavaborole</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000935" MajorTopicYN="N">Antifungal Agents</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001896" MajorTopicYN="N">Boron Compounds</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019086" MajorTopicYN="N">Bridged Bicyclo Compounds, Heterocyclic</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077768" MajorTopicYN="N">Ciclopirox</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015725" MajorTopicYN="N">Fluconazole</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017964" MajorTopicYN="N">Itraconazole</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053685" MajorTopicYN="N">Laser Therapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053758" MajorTopicYN="N">Nanoparticles</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014009" MajorTopicYN="N">Onychomycosis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010778" MajorTopicYN="N">Photochemotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058626" MajorTopicYN="N">Plasma Gases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020551" MajorTopicYN="N">Pulse Therapy, Drug</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D055502" MajorTopicYN="Y">Secondary Prevention</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077291" MajorTopicYN="N">Terbinafine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">booster therapy</Keyword>
        <Keyword MajorTopicYN="N">ciclopirox</Keyword>
        <Keyword MajorTopicYN="N">clinical cure</Keyword>
        <Keyword MajorTopicYN="N">complete cure</Keyword>
        <Keyword MajorTopicYN="N">efinaconazole</Keyword>
        <Keyword MajorTopicYN="N">fluconazole</Keyword>
        <Keyword MajorTopicYN="N">fungal nail infection</Keyword>
        <Keyword MajorTopicYN="N">itraconazole</Keyword>
        <Keyword MajorTopicYN="N">lasers</Keyword>
        <Keyword MajorTopicYN="N">mycologic cure</Keyword>
        <Keyword MajorTopicYN="N">onychomycosis</Keyword>
        <Keyword MajorTopicYN="N">photodynamic therapy</Keyword>
        <Keyword MajorTopicYN="N">plasma therapy</Keyword>
        <Keyword MajorTopicYN="N">pulse dosing</Keyword>
        <Keyword MajorTopicYN="N">tavaborole</Keyword>
        <Keyword MajorTopicYN="N">terbinafine</Keyword>
        <Keyword MajorTopicYN="N">treatment</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>3</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>4</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>7</Month>
          <Day>1</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29959962</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jaad.2018.05.1260</ArticleId>
        <ArticleId IdType="pii">S0190-9622(18)32187-X</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
